Thetis is an emerging pharmaceutical company developing a portfolio of Omega-3 based new molecular entities with enhanced bioavailability that modulate lipid-signaling pathways to target cardio-metabolic diseases.

Thetis’s proprietary HEALER℠ Technology (High Efficiency Amino Lipid Enabled Release) uses transformative ionic chemistry to revitalize proven therapeutic agents. This technology is internally generated and company owned, and opens the door to regulatory efficiency, enabling expedient development and registration. The foundation for the HEALER℠ Technology is chemical transformation of Omega-3 components EPA and DHA into solid, stable ionic salts that have major pharmacological and pharmacokinentic advantages over existing Omega-3 compounds and uniquely address the major deficits in diabetes and dyslipidemia.

Thetis has completed clinical studies on an exploratory drug candidate and is undertaking pre-clinical studies to file additional Investigational New Drug (IND) applications on its lead candidates (TP-252, TP-113 and TP-110) with the U.S. Food and Drug Administration (FDA).